U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Collaborating Centre for Mental Health (UK). Drug Misuse: Opioid Detoxification. Leicester (UK): British Psychological Society (UK); 2008. (NICE Clinical Guidelines, No. 52.)

Cover of Drug Misuse

Drug Misuse: Opioid Detoxification.

Show details

11. REFERENCES

  1. Adi Y, Juarez-Garcia A, Wang D, et al. Oral Naltrexone as a Treatment for Relapse Prevention in Formerly Opioid-Dependent Drug Users: a Systematic Review and Economic Evaluation. Health Technology Assessment. Tunbridge Wells: Gray Publishing; 2007. pp. 6pp. 1–104. http://www​.hta.ac.uk/project/1491.asp . [PubMed: 17280624]
  2. Advisory Council on the Misuse of Drugs (ACMD). Drug Misuse and the Environment. London: The Stationery Office; 1998.
  3. Advisory Council on the Misuse of Drugs (ACMD). Hidden Harm: Responding to the Needs of Children of Problem Drug Users. London: Home Office; 2003.
  4. Advisory Council on the Misuse of Drugs (ACMD). Hidden Harm Three Years On: Realities, Challenges and Opportunities. London: Home Office; 2007.
  5. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Quality and Safety in Health Care. 2003;12:18–23. [PMC free article: PMC1743672] [PubMed: 12571340]
  6. All-Party Parliamentary Group on Prison Health. The Mental Health Problem in UK HM Prisons. London: House of Commons; 2006.
  7. American Psychiatric Association (APA). DSM-IV Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Washington, DC: APA; 1994.
  8. Anglin MD, Hser Y. Treatment of drug abuse, Drugs and Crime. Tonry M, Wilson JQ, editors. Chicago: University of Chicago Press; 1990. pp. 393–460.
  9. Anthony JC, Petronis KR. Early onset drug use and later drug problems. Drug and Alcohol Dependence. 1995;40:9–15. [PubMed: 8746919]
  10. Araujo L, Goldberg P, Eyma J, et al. The effect of anxiety and depression on completion/withdrawal status in patients admitted to substance abuse detoxification program. Journal of Substance Abuse Treatment. 1996;13:61–66. [PubMed: 8699544]
  11. Armstrong J, Little M, Murray L. Emergency department presentations of naltrexone-accelerated detoxification. Academic Emergency Medicine. 2003;10:860–866. [PubMed: 12896887]
  12. Arnold-Reed DE, Hulse GK. A comparison of rapid (opioid) detoxification with clonidine-assisted detoxification for heroin-dependent persons. Journal of Opioid Management. 2005;1:17–23. [PubMed: 17315407]
  13. Assadi SM, Hafezi M, Mokri A, et al. Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial. Journal of Substance Abuse Treatment. 2004;27:75–82. [PubMed: 15223097]
  14. Bachman JG, Wadsworth KN, O’Malley P, et al. Smoking, Drinking and Drug Use in Young Adulthood: the Impacts of New Freedoms and Responsibilities. Mahwah, NJ: Lawrence Erlbaum; 1997.
  15. Backmund M, Meyer K, Eichenlaub D, et al. Predictors for completing an inpatient detoxification program among intravenous heroin users, methadone substituted and codeine substituted patients. Drug and Alcohol Dependence. 2001;64:173–180. [PubMed: 11543987]
  16. Bancroft A, Carty A, Cunningham-Burley S, et al. Support for the Families of Drug Users: a Review of the Literature. Edinburgh; Scottish Executive Interventions Unit: 2002.
  17. Banys P, Tusel DJ, Sees KL, et al. Low (40 mg) versus high (80 mg) dose methadone in a 180-day heroin detoxification program. Journal of Substance Abuse Treatment. 1994;11:225–232. [PubMed: 8072050]
  18. Barnaby B, Drummond C, McCloud A, et al. Substance misuse in psychiatric inpatients: comparison of a screening questionnaire survey with case notes. British Medical Journal. 2003;327:783–784. [PMC free article: PMC214087] [PubMed: 14525876]
  19. Barnard M, McKeganey N. The impact of parental problem drug use on children: what is the problem and what can be done to help? Addiction. 2004;99:552–559. [PubMed: 15078229]
  20. Bearn J, Gossop M, Strang J. Randomised double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal. Drug and Alcohol Dependence. 1996;43:87–91. [PubMed: 8957147]
  21. Beck AT. Cognitive therapy: past, present, and future. Journal of Consulting and Clinical Psychology. 1993;61:194–198. [PubMed: 8473571]
  22. Bennett T, Holloway K, Williams T. Drug Use and Offending: Summary Results from the First Year of the NEW-ADAM Research Programme, Home Office Research Findings no: 148. London: Home Office; 2001.
  23. Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-Analysis Blinding Study Group. Lancet. 1997;350:185–186. [PubMed: 9250191]
  24. Best D, Campbell A, O’Grady A. The NTA’s First Annual User Satisfaction Survey 2005. London: NTA; 2006a.
  25. Best D, Day E, Morgan B. Addiction Careers and the Natural History of Change. London: NTA; 2006b.
  26. Beswick T, Best D, Bearn J, et al. The effectiveness of combined naloxone/lofexidine in opiate detoxification: results from a double-blind randomized and placebo-controlled trial. American Journal on Addictions. 2003;12:295–305. [PubMed: 14504022]
  27. Bickel WK, Amass L. Buprenorphine treatment of opioid dependence: a review. Experimental and Clinical Psychopharmacology. 1995;3:477–489.
  28. Bickel WK, Amass L, Higgins ST, et al. Effects of adding behavioral treatment to opioid detoxification with buprenorphine. Journal of Consulting and Clinical Psychology. 1997;65:803–810. [PubMed: 9337499]
  29. Biernacki P. Pathways from Heroin Addiction Recovery Without Treatment. Philadelphia: Temple University Press; 1986.
  30. Bradley BP, Gossop M, Phillips GT, et al. The development of an opiate withdrawal scale (OWS). British Journal of Addiction. 1987;82:1139–1142. [PubMed: 3479162]
  31. British Medical Association. Focus on enhanced services. 2004. [Accessed April 2007]. http://www​.bma.org.uk/ap​.nsf/Content/focusenhanced0104 .
  32. Brugal MT, Domingo-Salvany A, Puig R, et al. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and AIDS in a cohort of heroin users in Spain. Addiction. 2005;100:981–989. [PubMed: 15955014]
  33. Carnwath T, Hardman J. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug and Alcohol Dependence. 1998;50:251–254. [PubMed: 9649979]
  34. Carreno JE, Bobes J, Brewer C, et al. 24-hour opiate detoxification and antagonist induction at home – the ‘Asturian method’: a report on 1368 procedures. Addiction Biology. 2002;7:243–250. [PubMed: 12006220]
  35. Carroll KM, Onken LS. Behavioural therapies for drug abuse. American Journal of Psychiatry. 2005;162:1452–1460. [PMC free article: PMC3633201] [PubMed: 16055766]
  36. Center for Substance Abuse Treatment (CSAT). Detoxification and Substance Abuse Treatment Treatment Improvement Protocol (TIP) Series 45. Rockville, MD: SAMHSA; 2006.
  37. Cheskin LJ, Fudala PJ, Johnson RE. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug and Alcohol Dependence. 1994;36:115–121. [PubMed: 7851278]
  38. Chivite-Matthews N, Richardson A, O’Shea J, et al. Drug Misuse Declared: Findings from the 2003/4 British Crime Survey. London: Home Office; 2005.
  39. Christo G, Spurrell S, Alcorn R. Validation of the Christo Inventory for Substance-Misuse Services (CISS): a simple outcome evaluation tool. Drug and Alcohol Dependence. 2000;59:189–197. [PubMed: 10891633]
  40. Cochrane Collaboration. Review Manager (RevMan) [computer program] Version 425 for Windows. Oxford; The Cochrane Collaboration: 2005.
  41. Collins ED, Kleber HD, Whittington RA, et al. Anaesthesia-assisted vs. buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. The Journal of the American Medical Association. 2005;294:903–913. [PubMed: 16118380]
  42. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and Buprenorphine for the Management of Opioid Dependence: a Systematic Review and Economic Evaulation. Health Techonology Assessment. Tunbridge Wells: Gray Publishing; 2007. pp. 1–190. http://www​.hta.ac.uk/project/1492.asp . [PubMed: 17313907]
  43. Connors GJ, Carroll KM, DiClemente CC, et al. The therapeutic alliance and its relationship to alcoholism treatment participation and outcome. Journal of Consulting and Clinical Psychology. 1997;65:588–598. [PubMed: 9256560]
  44. Connors GJ, DiClemente CC, Derman KH, et al. Predicting the therapeutic alliance in alcoholism treatment. Journal of Studies on Alcohol. 2000;61:139–149. [PubMed: 10627108]
  45. Cook TM, Collins PD. Rapid opioid detoxification under anaesthesia. Hospital Medicine. 1998;59:245–247. [PubMed: 9722357]
  46. Copello AG, Velleman RD, Templeton LJ. Family interventions in the treatment of alcohol and drug problems. Drug and Alcohol Review. 2005;24:369–385. [PubMed: 16234133]
  47. Corkery JM, Schifano F, Ghodse AH, et al. The effects of methadone and its role in fatalities. Human Psychopharmacology. 2004;19:565–576. [PubMed: 15378662]
  48. Crome IB, Bloor R, Thom B. Screening for illicit drug use in psychiatric hospitals: whose job is it? Advances in Psychiatric Treatment. 2006;12:375–383.
  49. Cucchia AT, Monnat M, Spagnoli J, et al. Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results. Drug and Alcohol Dependence. 1998;52:243–250. [PubMed: 9839150]
  50. Curtis L, Netten A. Unit Costs of Health and Social Care 2005. Canterbury: PSSRU; 2005.
  51. Curtis L, Netten A. Unit Costs of Health and Social Care 2006. Canterbury: PSSRU; 2006.
  52. Dackis C, O’Brien C. Neurobiology of addiction: treatment and public policy ramifications. Nature Neuroscience. 2005;8:1431–1436. [PubMed: 16251982]
  53. Darke S, Zador D. Fatal heroin ‘overdose’: a review. Addiction. 1996;91:1765–1772. [PubMed: 8997759]
  54. Darke S, Hall W, Wodak A, et al. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. British Journal of Addiction. 1992;87:733–742. [PubMed: 1591524]
  55. Davoli M, Baragagli AM, Perucci CA, et al. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE Study, a national multisite prospective cohort study. Addiction. in press. [PubMed: 18031430]
  56. Dawe S, Griffiths P, Gossop M, et al. Should opiate addicts be involved in controlling their own detoxification? A comparison of fixed versus negotiable schedules. British Journal of Addiction. 1991;86:977–982. [PubMed: 1912752]
  57. Day E, Ison J, Keaney F, et al. A National Survey of Inpatient Drug Services in England. London: NTA; 2005.
  58. Day E. Outpatient vs Inpatient Opioid Detoxification (OPIOiD) Study. 2007. Unpublished manuscript.
  59. DeJong CA, Laheij RJ, Krabbe PF. General anaesthesia does not improve outcome in opioid antagonist detoxification treatment: a randomized controlled trial. Addiction. 2005;100:206–215. [PubMed: 15679750]
  60. Department of Health (DH). Drug Misuse and Dependence - Guidelines on Clinical Management. London: Stationery Office; 1999.
  61. Department of Health (DH). Clinical Management of Drug Dependence in an Adult Prison Setting. London: DH; 2006.
  62. Department of Health (DH). Drug Misuse and Dependence – Guidelines on Clinical Management: Update 2007. London: DH; in press.
  63. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials. 1986;7:177–188. [PubMed: 3802833]
  64. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. British Medical Journal, 3. 1996;313:275–283. [PMC free article: PMC2351717] [PubMed: 8704542]
  65. Drummond C, Turkington D, Rahman MZ, et al. Chlordiazepoxide vs. methadone in opiate withdrawal: a preliminary double blind trial. Drug and Alcohol Dependence. 1989;23:63–71. [PubMed: 2646089]
  66. Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: methods of developing guidelines for efficient drug use in primary care. British Medical Journal. 1998;316:1232–1235. [PMC free article: PMC1112989] [PubMed: 9553004]
  67. Elman I, D’Ambra MN, Krause S, et al. Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes. Drug and Alcohol Dependence. 2001;61:163–172. [PubMed: 11137281]
  68. Epstein DH, Hawkins WE, Covi L, et al. Cognitive-behavioral therapy plus contingency management for cocaine use: findings during treatment and across 12-month follow-up. Psychology of Addictive Behaviors. 2003;17:73–82. [PMC free article: PMC1224747] [PubMed: 12665084]
  69. Favrat B, Zimmermann G, Zullino D, et al. Opioid antagonist detoxification under anaesthesia versus traditional clonidine detoxification combined with an additional week of psychosocial support: a randomized clinical trial. Drug and Alcohol Dependence. 2006;81:109–116. [PubMed: 16024184]
  70. Ford C, Morton S, Lintzeris N, et al. Guidance for the Use of Buprenorphine for the Treatment of Opioid Dependence in Primary Care. 2nd edn. London: Royal College of General Practitioners; 2004.
  71. Franken IH, Hendriks VM. Predicting outcome of inpatient detoxification of substance abusers. Psychiatric Services. 1999;50:813–817. [PubMed: 10375152]
  72. Frischer M, Goldberg D, Rahman M, et al. Mortality and survival among a cohort of drug injectors in Glasgow, 1982–1994. Addiction. 1997;92:419–427. [PubMed: 9177063]
  73. Frischer M, Hickman M, Kraus L, et al. A comparison of different methods for estimating the prevalence of problematic drug misuse in Great Britain. Addiction. 2001;96:1465–1476. [PubMed: 11571065]
  74. Frischer M, Crome I, MacLeod J, et al. Substance misuse and psychiatric illness: a prospective observational study using the general practice research database. Journal of Epidemiology and Community Health. 2005;59:847–850. [PMC free article: PMC1732930] [PubMed: 16166357]
  75. Galanter M, Dermatis H, Glickman L, et al. Network therapy: decreased secondary opioid use during buprenorphine maintenance. Journal of Substance Abuse Treatment. 2004;26:313–318. [PubMed: 15182896]
  76. George S, Braithwaite RA. Use of on-site testing for drugs of abuse. Clinical Chemistry. 2002;48:1639–1646. [PubMed: 12324478]
  77. Gerra G, Marcato A, Caccavari R, et al. Clonidine and opiate receptor antagonists in the treatment of heroin addiction. Journal of Substance Abuse Treatment. 1995;12:35–41. [PubMed: 7752296]
  78. Gerra G, Zaimovic A, Rustichelli P, et al. Rapid opiate detoxification in outpatient treatment: relationship with naltrexone compliance. Journal of Substance Abuse Treatment. 2000;18:185–191. [PubMed: 10716102]
  79. Gerra G, Zaimovic A, Giusti F, et al. Lofexidine versus clonidine in rapid opiate detoxification. Journal of Substance Abuse Treatment. 2001;21:11–17. [PubMed: 11516922]
  80. Gerstein DR, Harwood HJ. Treating Drug Problems, Vol 1: A Study of the Evolution, Effectiveness, and Financing of Public and Private Drug Treatment Systems. Washington, DC: National Academy Press; 1990. [PubMed: 25144071]
  81. Ghodse H, Myles J, Smith SE. Clonidine is not a useful adjunct to methadone gradual detoxification in opioid addiction. The British Journal of Psychiatry. 1994;165:370–374. [PubMed: 7994508]
  82. Gibson AE, Doran CM, Bell JR, et al. A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. The Medical Journal of Australia. 2003;179:38–42. [PubMed: 12831383]
  83. Godfrey C, Eaton G, McDougall C, et al. The Economic and Social Costs of Class A Drug Use in England and Wales. Home Office Research Study 249. London: Home Office; 2002.
  84. Gold CG, Cullen DJ, Scott Gonzales MS, et al. Rapid opioid detoxification during general anesthesia. Anesthesiology. 1999;91:1639–1647. [PubMed: 10598605]
  85. Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug and Alcohol Dependence. 1988;21:253–259. [PubMed: 3048954]
  86. Gossop M. The Development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviours. 1990;15:487–490. [PubMed: 2248123]
  87. Gossop M, Strang J. Price, cost and value of opiate detoxification treatments-Reanalysis of data from two randomized trials. British Journal of Psychiatry. 2000;177:262–266. [PubMed: 11040889]
  88. Gossop M, Johns A, Green L. Opiate withdrawal: inpatient versus outpatient programmes and preferred versus random assignment to treatment. British Medical Journal. 1986;293:103–104. [PMC free article: PMC1340840] [PubMed: 3089407]
  89. Gossop M, Griffiths P, Bradley B, et al. Opiate withdrawal symptoms in response to 10-day and 21-day methadone withdrawal programmes. The British Journal of Psychiatry. 1989;154:360–363. [PubMed: 2688778]
  90. Gossop M, Battersby M, Strang J. Self-detoxification by opiate addicts. A preliminary investigation. The British Journal of Psychiatry. 1991;159:208–212. [PubMed: 1663410]
  91. Gossop M, Darke S, Griffiths P, et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995;90:607–614. [PubMed: 7795497]
  92. Gossop M, Marsden J, Stewart D. NTORS at 1 Year. The National Treatment Outcome Research Study: Changes in Substance Use, Health and Criminal Behaviours 1 Year After Intake. London: DH; 1998.
  93. Gossop M, Marsden J, Stewart D, et al. Patterns of drinking and drinking outcomes among drug misusers: 1-year follow-up results. Journal of Substance Abuse Treatment. 2000a;19:45–50. [PubMed: 10867300]
  94. Gossop M, Marsden J, Stewart D, et al. Reductions in acquisitive crime and drug use after treatment of addiction problems: 1-year follow up outcomes. Drug and Alcohol Dependence. 2000b;58:165–172. [PubMed: 10669068]
  95. Gossop M, Marsden J, Stewart D, et al. The National Treatment Outcome Research Study (NTORS): 4–5 year follow-up results. Addiction. 2003;98:291–303. [PubMed: 12603229]
  96. Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group. Grading quality of evidence and strength of recommendations. British Medical Journal. 2004;328:1490. [PMC free article: PMC428525] [PubMed: 15205295]
  97. Green L, Gossop M. Effects of information on the opiate withdrawal syndrome. British Journal of Addiction. 1988;83:305–309. [PubMed: 3365510]
  98. Griffith JD, Rowan-Szal GA, Roark RR, et al. Contingency management in outpatient methadone treatment: a meta-analysis. Drug and Alcohol Dependence. 2000;58:55–66. [PubMed: 10669055]
  99. Gronholm M, Lillsunde P. A comparison between on-site immunoassay drug-testing devices and laboratory results. Forensic Science International. 2001;121:37–46. [PubMed: 11516886]
  100. Hall SM, Bass A, Hargreaves WA, et al. Contingency management and information feedback in outpatient heroin detoxification. Behavior Therapy. 1979;10:443–451.
  101. Hamilton RJ, Olmedo RE, Shah S, et al. Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Academic Emergency Medicine. 2002;9:63–68. [PubMed: 11772672]
  102. Handelsman L, Cochrane KJ, Aronson MJ, et al. Two new rating scales for opiate withdrawal. The American Journal of Drug and Alcohol Abuse. 1987;13:293–308. [PubMed: 3687892]
  103. Hanson GR, Venturelli PJ, Fleckenstein AE. Drugs and Society. 9th edn. London: Jones and Bartlett; 2006.
  104. Hartz D, Meek P, Piotrowski NA, et al. A cost-effectiveness and cost-benefit analysis of contingency contracting-enhanced methadone detoxification treatment. American Journal of Drug and Alcohol Abuse. 1999;25:207–218. [PubMed: 10395156]
  105. Hattenschwiler J, Ruesch P, Hell D. Effectiveness of inpatient drug detoxification: links between process and outcome variables. European Addiction Research. 2000;6:123–131. [PubMed: 11060476]
  106. Hay G, Gannon M, MacDougall J, et al. Singleton N, Murray R, Tinsley L, editors. Measuring Different Aspects of Problem Drug Use: Methodological Developments. London: Home Office; 2006. Local and national estimates of the prevalence of opiate use and/or crack cocaine use (2004/05). http://www​.homeoffice​.gov.uk/rds/pdfs06/rdsolr1606.pdf .
  107. Health Protection Agency, Health Protection Scotland, National Public Health Service for Wales, et al. Shooting Up: Infections Among Injecting Drug Users in the United Kingdom 2004. An Update: October 2005. London: Health Protection Agency; 2005.
  108. Health Protection Agency, Health Protection Scotland, National Public Health Service for Wales, et al. Shooting Up: Infections Among Injecting Drug Users in the United Kingdom 2005. An Update: October 2006. London: Health Protection Agency; 2006.
  109. Hensel M, Wolter S, Kox WJ. EEG controlled rapid opioid withdrawal under general anaesthesia. British Journal of Anaesthesia. 2000;84:236–238. [PubMed: 10743458]
  110. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology. 1997;129:99–111. [PubMed: 9040115]
  111. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine. 2002;21:1539–1558. [PubMed: 12111919]
  112. Higgins ST, Stitzer ML, Bigelow GE, et al. Contingent methadone dose increases as a method for reducing illicit opiate use in detoxification patients. NIDA Research Monograph. 1984;55:178–184. [PubMed: 6443376]
  113. Higgins ST, Stitzer ML, Bigelow GE, et al. Contingent methadone delivery: effects on illicit-opiate use. Drug and Alcohol Dependence. 1986;17:311–322. [PubMed: 3757767]
  114. HM Prison Service. Prison Service Order 3601: Mandatory Drug Testing. London: HM Prison Service; 2005.
  115. Hoffman WE, Berkowitz R, McDonald T, et al. Ultra-rapid opioid detoxification increases spontaneous ventilation. Journal of Clinical Anesthesia. 1998;10:372–376. [PubMed: 9702615]
  116. Home Office. Updated Drug Strategy. 2002. [accessed November 2006]. http://www​.drugs.gov​.uk/drug-strategy/uk-government/
  117. Home Office Drug Strategy Directorate. Integrated Drug Treatment System. The First 28 Days: Psychosocial Support. First Wave Model. London: Stationery Office; 2006.
  118. Howells C, Allen S, Gupta J, et al. Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence. 2002;67:169–176. [PubMed: 12095666]
  119. Hser YI, Hoffman V, Grella D, et al. A 33-year follow up of narcotics addicts. Archives of General Psychiatry. 2001;58:503–508. [PubMed: 11343531]
  120. Ison J, Day E, Fisher K, et al. Self-detoxification from opioid drugs. Journal of Substance Use. 2006;11:81–88.
  121. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Controlled Clinical Trials. 1996;17:1–12. [PubMed: 8721797]
  122. Jaffe JH. Drug dependence: opioids, non-narcotics, nicotine and caffeine, Comprehensive Textbook of Psychiatry – V. Kaplan HI, Sadock BJ, editors. Baltimore, MD: Williams and Wilkins; 1989. p. 648 .
  123. Janiri L, Mannelli P, Persico AM, et al. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug and Alcohol Dependence. 1994;36:139–145. [PubMed: 7851281]
  124. Jiang Z. Rapid detoxification with clonidine for heroin addiction. A comparative study on its efficacy versus methadone. Chinese Journal of Neurology and Psychiatry. 1993;26:10–13.
  125. Joe GW, Chastain RL, Simpson DD. Length of careers, Opioid Addiction and Treatment: A 12-Year Follow-Up. Simpson DD, Sells SB, editors. Malabar, FL: Robert E. Keiger Publishing Company; 1990. pp. 103–120.
  126. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. The Journal of the American Medical Association. 1992;267:2750–2755. [PubMed: 1578593]
  127. Jordan JB. Acupuncture treatment for opiate addiction: a systematic review. Journal of Substance Abuse Treatment. 2006;30:309–314. [PubMed: 16716845]
  128. Judd A, Hickman M, Jones S, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. British Medical Journal. 2005;330:24–25. [PMC free article: PMC539846] [PubMed: 15533854]
  129. Kahn A, Mumford JP, Rogers GA, et al. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug and Alcohol Dependence. 1997;44:57–61. [PubMed: 9031821]
  130. Kandel DB, Davies M, Karus D, et al. The consequences in young adulthood of adolescent drug involvement. An overview. Archives of General Psychiatry. 1986;43:746–754. [PubMed: 3729669]
  131. Katz EC, Chutuape MA, Jones H, et al. Abstinence incentive effects in a short-term outpatient detoxification program. Experimental and Clinical Psychopharmacology. 2004;12:262–268. [PubMed: 15571443]
  132. Kleber HD, Riordan CE, Rounsaville B, et al. Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry. 1985;42:391–394. [PubMed: 3977557]
  133. Kumpfer KL, Bluth B. Parent/child transactional processes predictive of resilience or vulnerability to ‘substance abuse disorders’ Substance Use and Misuse. 2004;39:671–698. [PubMed: 15202804]
  134. Krabbe PF, Koning JP, Heinen N, et al. Rapid detoxification from opioid dependence under general anaesthesia versus standard methadone tapering: abstinence rates and withdrawal distress experiences. Addiction Biology. 2003;8:351–358. [PubMed: 13129838]
  135. Leichsenring F, Rabung S, Leibing E. The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders: a meta-analysis. Archives of General Psychiatry. 2004;61:1208–1216. [PubMed: 15583112]
  136. Lima Reisser A, Lima MS, Soares BGO, et al. Carbamazepine for cocaine dependence. Cochrane Database of Systematic Reviews. 2002;2:CD002023. [PubMed: 12076433]
  137. Liddel J, Williamson M, Irwig L. Method for Evaluating Research and Guideline Evidence. Sydney: New South Wales Health Department; 1996.
  138. Lin SK, Strang J, Su LW, et al. Double-blind randomized controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug and Alcohol Dependence. 1997;48:127–133. [PubMed: 9363412]
  139. Ling W, Amass L, Shoptaw S, et al. A multi-center randomised trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005;100:1090–1100. [PMC free article: PMC1480367] [PubMed: 16042639]
  140. Lingford-Hughes A, Nutt D. Neurobiology of addiction and implications for treatment. The British Journal of Psychiatry. 2003;182:97–100. [PubMed: 12562734]
  141. Lintzeris N, Bell J, Brammer G, et al. A randomised controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction. 2002;97:1395–1404. [PubMed: 12410780]
  142. Lipton D, Maranda M. Detoxification from heroin dependency: an overview of method and effectiveness, Evaluation of Drug Treatment Programs. Stimmel B, editor. New York: Hawarth Press; 1983.
  143. Loimer N, Schmid RW, Presslich O, et al. Continuous naloxone administration suppresses opiate withdrawal symptoms in human opiate addicts during detoxification treatment. Journal of Psychiatric Research. 1989;23:81–86. [PubMed: 2547057]
  144. Loimer N, Lenz K, Schmid R, et al. Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates. The American Journal of Psychiatry. 1991;148:933–935. [PubMed: 2053636]
  145. Luty J, Perry V, Umoh O, et al. Validation and development of a self-report outcome measure (MAP-sc) in opiate addiction. Psychiatric Bulletin. 2006;30:134–139.
  146. McCambridge J, Gossop M, Beswick T, et al. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone. Drug and Alcohol Dependence. 2007;88:91–95. [PubMed: 17064857]
  147. McCaul ME, Stitzer ML, Bigelow GE, et al. Contingency management interventions: effects on treatment outcome during methadone detoxification. Journal of Applied Behavior Analysis. 1984;17:35–43. [PMC free article: PMC1307916] [PubMed: 6725168]
  148. McGregor C, Ali R, White JM, et al. A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. Drug and Alcohol Dependence. 2002;68:5–14. [PubMed: 12167548]
  149. McLellan AT, Luborksy L, Woody GE, et al. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. The Journal of Nervous and Mental Disease. 1980;168:26–33. [PubMed: 7351540]
  150. Makela K. Studies of the reliability and validity of the Addiction Severity Index. Addiction. 2004;99:398–410. [PubMed: 15049734]
  151. Maldonado R. Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neuroscience and Biobehavioural Reviews. 1997;21:91–104. [PubMed: 8994212]
  152. Mann T. Clinical Guidelines: Using Clinical Guidelines to Improve Patient Care Within the NHS. London: Department of Health; 1996.
  153. Marsch LA, Bickel WK, Badger GJ, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Archives of General Psychiatry. 2005;62:1157–1164. [PubMed: 16203961]
  154. Marsden J, Gossop M, Stewart D, et al. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction. 1998;93:1857–1867. [PubMed: 9926574]
  155. Marsden J, Gossop M, Stewart D, et al. Psychiatric symptoms among clients seeking treatment for drug dependence. Intake data from the National Treatment Outcome Research Study. British Journal of Psychiatry. 2000;176:285–289. [PubMed: 10755078]
  156. Marsden J, Strang J, Lavoie D, et al. Drug misuse, Health Care Needs Assessment: The Epidemiologically Based Needs Assessment Reviews. Stevens A, Raftery J, Mant J, et al., editors. Abingdon: Radcliffe Medical Press; 2004. pp. 367–450.
  157. Matrix Research and Consultancy & NACRO. Home Office Research Study 286. Evaluation of Drug Testing in the Criminal Justice System. London: Home Office; 2004.
  158. Mattick RP, Hall W. Are detoxification programmes effective? Lancet. 1996;347:97–100. [PubMed: 8538351]
  159. Mattick RP, Digiusto E, Doran CM, et al. National Evaluation of Pharmacotherapies for Opioid Dependence: Report of Results and Recommendations. Sydney: National Drug and Alcohol Research Centre; 2001.
  160. Maude-Griffin PM, Hohenstein JM, Humfleet GL, et al. Superior efficacy of cognitive-behavioural therapy for urban crack cocaine abusers: main and matching effects. Journal of Consulting and Clinical Psychology. 1998;66:832–837. [PubMed: 9803702]
  161. Mule SJ, Casella GA. Rendering the ‘poppy seed defense’ defenseless: identification of 6-monoacetylmorphine in urine by gas chromatography/mass spectroscopy. Clinical Chemistry. 1988;34:1427–1430. [PubMed: 3390911]
  162. National Academy of Clinical Biochemistry (NACB). Laboratory Medicine Practice Guidelines. Evidence-Based Practice for Point-of-Care Testing. Washington, DC: AACC Press; 2006.
  163. National Collaborating Centre for Mental Health (NCCMH). Drug Misuse: Psychosocial Interventions. Leicester & London: The British Psychological Society and the Royal College of Psychiatrists; 2008. [PubMed: 21834194]
  164. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. The Journal of the American Medical Association. 1998;280:1936–1943. [PubMed: 9851480]
  165. National Institute for Health and Clinical Excellence (NICE). Depression: Management of Depression in Primary and Secondary Care. NICE clinical guideline no. 23. London: NICE; 2004.
  166. National Institute for Health and Clinical Excellence (NICE). Social Value Judgements: Principles for the Development of NICE Guidance. 2005. http://www​.nice.org.uk/page​.aspx?o=283494 . [PubMed: 27905706]
  167. National Institute for Health and Clinical Excellence NICE. The Guidelines Manual. London: NICE; 2006a. [PubMed: 27905714]
  168. National Institute for Health and Clinical Excellence NICE. The Guideline Development Process – An Overview for Stakeholders, the Public and the NHS. 2nd edn. London: NICE; 2006b.
  169. National Institute for Health and Clinical Excellence (NICE). Methadone and Buprenorphine for the Management of Opiod Dependence Evaluation Report. London: NICE; 2006c.
  170. National Institute for Health and Clinical Excellence (NICE). Drug Misuse: Psychosocial Interventions. NICE clinical guideline no. 51. London: NICE; 2007.
  171. National Institute on Drug Abuse (NIDA). Research Report Series Heroin Abuse and Addiction. Bethesda, MD: National Institutes of Health; 2005a.
  172. National Programme on Substance Abuse Deaths. Drug-Related Deaths in the UK – Annual Report 2005. London: International Centre for Drug Policy; 2005.
  173. National Treatment Agency for Substance Misuse (NTA). Models of Care for the Treatment of Adult Drug Misusers. Framework for Developing Local Systems of Effective Drug Misuse Treatment in England. Part 1: Summary for Commissioners and Managers Responsible for Implementation. London: NTA; 2002. http://www​.nta.nhs.uk/frameset​.asp?u=http://www​.nta.nhs.uk/publications​/mocsummary/CONTENTS.HTM .
  174. National Treatment Agency for Substance Misuse (NTA). Statistics from the National Drug Treatment Monitoring System (NDTMS) 1st April 2003–31st March 2004. London: NTA; 2005a. http://www​.nta.nhs.uk​/programme/national​/docs/NDTMS_200304_bulletin_Jul_05.doc .
  175. National Treatment Agency for Substance Misuse (NTA). Statistics for Drug Treatment Activity in England 2004/05 from the National Drug Treatment Monitoring System. 2005b. http://www​.nta.nhs.uk/news/050926.htm .
  176. National Treatment Agency for Substance Misuse (NTA). Models of Care for the Treatment of Adult Drug Misusers: Update 2005. London: NTA; 2005c.
  177. National Treatment Agency for Substance Misuse (NTA). Models of Care for the Treatment of Adult Drug Misusers: Update 2006. London: NTA; 2006.
  178. Nigam AK, Ray R, Tripathi BM. Buprenorphine in opiate withdrawal: a comparison with clonidine. Journal of Substance Abuse Treatment. 1993;10:391–394. [PubMed: 8257551]
  179. Noble A, Best D, Man LH, et al. Self-detoxification attempts among methadone maintenance patients: what methods and what success? Addictive Behaviors. 2002;27:575–584. [PubMed: 12188593]
  180. O’Connor PG, Carroll KM, Shi JM, et al. Three methods of opioid detoxification in a primary care setting. Annals of Internal Medicine. 1997;127:526–530. [PubMed: 9313020]
  181. O’Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques. The Journal of the American Medical Association. 1998;279:229–234. [PubMed: 9438745]
  182. Office for National Statistics (ONS). Retail Prices Index: Annual Index Numbers of Retail Prices 1948–2006. 2007. [accessed on 20/3/07]. http://www​.statistics​.gov.uk/StatBase/tsdataset​.asp?vlnk=7172 .
  183. Onken LS, Blaine JD, Boren JJ. Treatment for drug addiction: it won’t work if they don’t receive it. NIDA Research Monograph. 1997;165:1–3. [PubMed: 9243543]
  184. Oppenheimer E, Tobutt C, Taylor C, et al. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction. 1994;89:1299–1308. [PubMed: 7804091]
  185. Orford J. Addiction as excessive appetite. Addiction. 2001;96:15–31. [PubMed: 11177517]
  186. Peckham CS, Dezateux C. Issues underlying the evaluation of screening programmes. British Medical Bulletin. 1998;54:767–778. [PubMed: 10367413]
  187. Perez de los Cobos J, Trujols J, Ribalta E, et al. Cocaine use immediately prior to entry in an inpatient heroin detoxification unit as a predictor of discharges against medical advice. The American Journal of Drug and Alcohol Abuse. 1997;23:267–279. [PubMed: 9143638]
  188. Petitjean S, Von Bardeleben U, Weber M, et al. Buprenorphine versus methadone in opiate detoxification: preliminary results. Drug and Alcohol Dependence. 2002;66(Suppl 138)
  189. Petry NM, Martin B. Low-cost contingency management for treating cocaine- and opioid-abusing methadone patients. Journal of Consulting and Clinical Psychology. 2002;70:398–405. [PubMed: 11952198]
  190. Petry NM, Tedford J, Austin M, et al. Prize reinforcement contingency management for treating cocaine users: how low can we go, and with whom? Addiction. 2004;99:349–360. [PMC free article: PMC3709247] [PubMed: 14982548]
  191. Petry NM, Martin B, Simcic F Jr. Prize reinforcement contingency management for cocaine dependence: integration with group therapy in a methadone clinic. Journal of Consulting and Clinical Psychology. 2005;73:354–359. [PubMed: 15796645]
  192. Pirnay S, Borron SW, Giudicelli CP, et al. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction. 2004;99:978–988. [PubMed: 15265095]
  193. Ponizovsky AM, Grinshpoon A, Margolis A, et al. Well-being, psychosocial factors, and side-effects among heroin-dependent inpatients after detoxification using buprenorphine versus clonidine. Addictive Behaviours. 2006;31:2002–2013. [PubMed: 16524668]
  194. Prendergast M, Podus D, Finney J, et al. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006;101:1546–1560. [PubMed: 17034434]
  195. Prescott CA, Madden PAF, Stallings C. Challenges in genetic studies of the etiology of substance use and substance use disorders: introduction to the special issue. Behavioral Genetics. 2006;36:473–482. [PubMed: 16710779]
  196. Preston KL, Bigelow GE, Liebson IA. Self-administration of clonidine and oxazepam by methadone detoxification patients. NIDA Research Monograph. 1984;49:192–198. [PubMed: 6434959]
  197. Raistrick D, Bradshaw J, Tober G, et al. Development of the Leeds Dependence Questionnaire (LQD): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction. 1994;89:563–572. [PubMed: 8044122]
  198. Raistrick D, West D, Finnegan O, et al. A comparison of buprenorphine and lofexidine for community opiate detoxification: results from a randomized controlled trial. Addiction. 2005;100:1860–1867. [PubMed: 16367987]
  199. Rawson RA, Mann AJ, Tennant FS, et al. Efficacy of psychotherapeutic counselling during 21-day ambulatory heroin detoxification. Drug and Alcohol Dependence. 1983;12:197–200. [PubMed: 6653391]
  200. Rawson RA, Huber A, McCann M, et al. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Archives of General Psychiatry. 2002;59:817–824. [PubMed: 12215081]
  201. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study. The Journal of the American Medical Association. 1990;264:2511–2518. [PubMed: 2232018]
  202. Regier DA, Rae DS, Narrow WE, et al. Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. The British Journal of Psychiatry. 1998;173(Suppl 34):24–28. [PubMed: 9829013]
  203. Rocha L, Tatsukawa K, Chugani HT. Benzodiazepine receptor binding following chronic treatment with naloxone, morphine and met-enkephalin in normal rats. Brain Research. 1993;612:247–252. [PubMed: 8392430]
  204. Roe S, Man L. Drug Misuse Declared: Findings from the British Crime Survey 2005/06 – England and Wales. London: Home Office; 2006.
  205. Roozen HG, De Kan R, Van Den Brink W, et al. Dangers involved in rapid opioid detoxification while using opioid antagonists: dehydration and renal failure. Addiction. 2002;97:1071–1073. [PubMed: 12144610]
  206. Roozen HG, Boulogne JJ, Van Tulder MW, et al. A systematic review of the effectiveness of the community reinforcement approach in alcohol, cocaine and opioid addiction. Drug and Alcohol Dependence. 2004;74:1–13. [PubMed: 15072802]
  207. Roth A, Fonagy P. What works for whom?: A Critical Review of Psychotherapy Research. 2nd edn. New York: Guilford; 2004.
  208. Salehi M, Amanatkar M, Barekatain M. Tramadol versus methadone for the management of acute opioid withdrawal: an add-on study. Journal of Research in Medical Sciences. 2006;11:185–189.
  209. Samyn N, Van Haeren C. On-site testing of saliva and sweat with Drugwipe and determination of concentrations of drugs of abuse in saliva, plasma and urine of suspected users. International Journal of Legal Medicine. 2000;113:150–154. [PubMed: 10876986]
  210. San L, Cami J, Peri JM, et al. Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction. 1990;85:141–147. [PubMed: 1968773]
  211. San L, Fernandez T, Cami J, et al. Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin addicted patients. Journal of Substance Abuse Treatment. 1994;11:463–469. [PubMed: 7869468]
  212. Scherbaum N, Kluwig J, Meiering C, et al. Use of illegally acquired medical opioids by opiate-dependent patients in detoxification treatment. European Addiction Research. 2005;11:193–196. [PubMed: 16110226]
  213. Schneider U, Paetzold W, Eronat V, et al. Buprenorphine and carbamazepine as a treatment for detoxification of opiate addicts with multiple drug misuse: a pilot study. Addiction Biology. 2000;5:65–69. [PubMed: 20575820]
  214. Schweizer E, Rickels K, Case WG, et al. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Archives of General Psychiatry. 1991;48:448–452. [PubMed: 2021297]
  215. Scottish Executive. Integrated Care for Drug Users: Digest of Tools Used in the Assessment Process and Core Data Sets. Edinburgh: Scottish Executive; 2003.
  216. Scottish Intercollegiate Guidelines Network (SIGN). SIGN 50 A Guideline Developer’s Handbook. Edinburgh: SIGN; 2002.
  217. Seifert J, Metzner C, Paetzold W, et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone. Pharmacopsychiatry. 2002;35:159–164. [PubMed: 12237786]
  218. Senay EC, Dorus W, Showalter CV. Short-term detoxification with methadone. Annals of the New York Academy of Sciences. 1981;362:203–216. [PubMed: 7020530]
  219. Seoane A, Carrasco G, Cabre L, et al. Efficacy and safety of two new methods of rapid intravenous detoxification in heroin addicts previously treated without success. The British Journal of Psychiatry. 1997;171:340–345. [PubMed: 9373422]
  220. Shanahan MD, et al. A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addictive Behaviors. 2006;31:371–387. [PubMed: 15972245]
  221. Shreeram SS, McDonald T, Dennison S. Psychosis after ultrarapid opiate detoxification. The American Journal of Psychiatry. 2001;158:970. [PubMed: 11384923]
  222. Siegel S, Hinson RE, Krank MD, et al. Heroin ‘overdose’ death: contribution of drug-associated environmental cues. Science. 1982;216:436–437. [PubMed: 7200260]
  223. Silverman K, Wong CJ, Umbricht-Schneiter A, et al. Broad beneficial effects of cocaine abstinence reinforcement among methadone patients. Journal of Consulting and Clinical Psychology. 1998;66:811–824. [PubMed: 9803700]
  224. Sims H. Families in Focus: a Report on a Series of Consultative Conversations Held in Urban and Rural Areas of England During Late 2001 and Early 2002. London: Adfam; 2002.
  225. Singleton N, Farrell M, Meltzer H. Substance Misuse Among Prisoners in England and Wales. Further Analysis of Data from the ONS Survey of Psychiatric Morbidity Among Prisoners in England and Wales Carried Out in 1997 on Behalf of the Department of Health. London: ONS; 1999.
  226. Sivam SP, Nabeshima T, Ho IK. An analysis of GABA receptor changes in the discrete regions of mouse brain after acute and chronic treatments with morphine. Journal of Neurochemistry. 1982;39:933–939. [PubMed: 6288864]
  227. Sorensen JL, Hargreaves WA, Weinberg JA. Withdrawal from heroin in three or six weeks. Archives of General Psychiatry. 1982;39:167–171. [PubMed: 7065831]
  228. Specialist Clinical Addiction Network (SCAN). Inpatient Treatment of Drug and Alcohol Misusers in the National Health Service: SCAN Consensus Project/Final Report of the SCAN Inpatient Treatment Working Party. London: SCAN; 2006.
  229. Sperling D, Davis P, Wanigaratne S. Measuring Treatment Outcomes with Drug Misuse Clients. Leicester: British Psychological Society; 2003.
  230. Stitzer ML, McCaul ME, Bigelow GE, et al. Chronic opiate use during methadone detoxification: effects of a dose increase treatment. Drug and Alcohol Dependence. 1984;14:37–44. [PubMed: 6489151]
  231. Stitzer ML, Iguchi MY, Felch LJ. Contingent take-home incentive: effects on drug use of methadone maintenance patients. Journal of Consulting and Clinical Psychology. 1992;60:927–934. [PubMed: 1460154]
  232. Strain EC, Bigelow GE, Liebson IA, et al. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomised trial. The Journal of the American Medical Association. 1999;281:1000–1005. [PubMed: 10086434]
  233. Strang J, Gossop M. Comparison of linear versus inverse exponential methadone reduction curves in the detoxification of opiate addicts. Addictive Behaviours. 1990;15:541–547. [PubMed: 2075851]
  234. Strang J, Bearn J, Gossop M. Opiate detoxification under anaesthesia. The British Medical Journal. 1997a;315:1249–1250. [PMC free article: PMC2127814] [PubMed: 9390045]
  235. Strang J, Marks I, Dawe S, et al. Type of hospital setting and treatment outcome with heroin addicts. Results from a randomised trial. The British Journal of Psychiatry. 1997b;171:335–339. [PubMed: 9373421]
  236. Strang J, Sheridan J, Hunt C, et al. The prescribing of methadone and other opioids to addicts: national survey of GPs in England and Wales. The British Journal of General Practice. 2005;55:444–451. [PMC free article: PMC1472740] [PubMed: 15970068]
  237. Tai B, Blaine J. Naltrexone: an Antagonist Therapy for Heroin Addiction. Bethesda, MD: National Institutes of Health; 1997. http://www​.nida.nih.gov​/MeetSum/naltrexone.html .
  238. Tennant FS, Shannon JA. Detoxification from methadone maintenance: double blind comparison of two methods. Drug and Alcohol Dependence. 1978;3:83–92. [PubMed: 344019]
  239. Tennant FS, Russell BA, Casas SK, et al. Heroin detoxification. A comparison of propoxyphene and methadone. The Journal of the American Medical Association. 1975;232:1019–1022. [PubMed: 805264]
  240. The Royal College of Anaesthetists. Implementing and Ensuring Safe Sedation Practice for Healthcare Procedures in Adults. London: Royal College of Anaesthetists; 2001. http://www​.rcoa.ac.uk​/docs/safesedationpractice.pdf .
  241. Sheard L, Adams CE, Wright NMJ, et al. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project pilot study: protocol for a randomized controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification. BMC Trials. 2007;8:1. [PMC free article: PMC1780064] [PubMed: 17210080]
  242. Tomaszewski C, Runge J, Gibbs M, et al. Evaluation of a rapid bedside toxicology screen in patients suspected of drug toxicity. The Journal of Emergency Medicine. 2005;28:389–394. [PubMed: 15837018]
  243. Umbricht A, Montoya ID, Hoover DR, et al. Naltrexone shortened opioid detoxification with buprenorphine. Drug and Alcohol Dependence. 1999;56:181–190. [PubMed: 10529020]
  244. Umbricht A, Hoover DR, Tucker MJ, et al. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug and Alcohol Dependence. 2003;69:263–272. [PubMed: 12633912]
  245. United Kingdom Anti-Drugs Coordinating Unit. Tackling Drugs to Build a Better Britain: The Government’s 10-Year Strategy for Tackling Drug Misuse. London: Stationery Office; 1998.
  246. Van Ree JM, Niesink RJM, Van Wolfswinkel L, et al. Endogenous opioids and reward. European Journal of Pharmacology. 2000;405:89–101. [PubMed: 11033317]
  247. Verger P, Rotily M, Prudhomme J, et al. High mortality rates among inmates during the year following their discharge from a French prison. Journal of Forensic Sciences. 2003;48:614–616. [PubMed: 12762532]
  248. Verstraete AG. Detection times of drugs of abuse in blood, urine and oral fluid. Therapeutic Drug Monitoring. 2004;26:200–205. [PubMed: 15228165]
  249. Volkow N, Li TK. The neuroscience of addiction. Nature Neuroscience. 2005;8:1429–1430. [PubMed: 16251981]
  250. Volkow ND, Fowler JS, Wang GJ. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. Journal of Psychopharmacology. 1999;13:337–345. [PubMed: 10667609]
  251. Walsh SL, Preston KL, Stitzer M, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clinical Pharmacology and Therapeutics. 1994;55:569–580. [PubMed: 8181201]
  252. Wanigaratne S, Davis P, Pryce K, et al. The Effectiveness of Psychological Therapies on Drug Misusing Clients. London: NTA; 2005.
  253. Ward J, Henderson Z, Pearson G. One Problem Among Many: Drug Use Among Care Leavers in Transition to Independent Living. London: Home Office; 2003.
  254. Washburn AM, Fullilove RE, Fullilove MT, et al. Acupuncture heroin detoxification: a single-blind clinical trial. Journal of Substance Abuse Treatment. 1993;10:345–351. [PubMed: 8411294]
  255. Washton AM, Resnick RB. Clonidine versus methadone for opiate detoxification. Lancet. 1980;2:1297. [PubMed: 6108466]
  256. Weissman MM, Markowitz JC, Klerman GL. Comprehensive Guide to Interpersonal Therapy. New York: Basic Books; 2000.
  257. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs. 2003;35:253–259. [PubMed: 12924748]
  258. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94:961–972. [PubMed: 10707430]
  259. Wild TC, Roberts AB, Cooper EL. Compulsory substance abuse treatment: an overview of recent findings and issues. European Addiction Research. 2002;8:84–93. [PubMed: 11979011]
  260. Wilson BK, Elms RR, Thomson CP. Outpatient vs hospital methadone detoxification: an experimental comparison. The International Journal of the Addictions. 1975;10:13–21. [PubMed: 47848]
  261. Williams TM, Daglish MRC, Lingford-Hughes A, et al. Brain opioid receptor binding in early abstinence from opioid dependence: positron emission tomography study. The British Journal of Psychiatry. 2007;191:63–69. [PubMed: 17602127]
  262. Witton J, Keaney F, Strang J. They do things differently over there: doctors, drugs and the ‘British System’ of treating opiate addiction. Journal of Drug Issues. 2004;35:441–449.
  263. World Health Organization (WHO). Prisons, Drugs and Society: A Consensus Statement on Principles, Policies and Practices. Berne, Switzerland: WHO; 2001.
  264. World Health Organization (WHO). Lexicon of Alcohol and Drug Terms Published by the World Health Organization. 2006. [accessed 2006]. Available at: http://www​.who.int/substance_abuse​/terminology​/who_lexicon/en/
  265. World Health Organization (WHO), United Nations Office on Drugs and Crime (UNODC) & UNAIDS. Substitution Maintenance Therapy in the Management of Opioid Dependence and HIV/AIDS Prevention. Geneva: WHO; 2004.
  266. Wright NM, Sheard L, Tompkins CN, et al. Buprenorphine versus dihydrocodeine for opiate detoxification in primary care: a randomised controlled trial. BMC Family Practice. 2007a;8:3. [PMC free article: PMC1774569] [PubMed: 17210079]
  267. Yandoli D, Eisler I, Robbins C, et al. A comparative study of family therapy in the treatment of opiate users in a London drug clinic. Journal of Family Therapy. 2002;24:402–422.
  268. Zeng X, Lei L, Lu Y, et al. Treatment of heroinism with acupuncture at points of the Du Channel. Journal of Traditional Chinese Medicine. 2005;25:166–170. [PubMed: 16334715]
Copyright © 2008, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

Bookshelf ID: NBK50623

Views

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...